Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis (Q28187597)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11487531%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

title

Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11487531%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11487531%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

author name string

S S Rebello

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11487531%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

R G Bentley

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11487531%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

S R Morgan

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11487531%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

C J Kasiewski

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11487531%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

V Chu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11487531%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

M H Perrone

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11487531%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

language of work or name

English

0 references

publication date

1 August 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11487531%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Pharmacology

10 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11487531%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

volume

133

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11487531%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11487531%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

page(s)

1190-1198

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11487531%20AND%20SRC:MED&resulttype=core&format=json

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

10 November 2019

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1572886

Platelet-dependent and procoagulant mechanisms in arterial thrombosis.

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1572886

Importance of factor Xa in determining the procoagulant activity of whole-blood clots

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1572886

Role of platelet-activating factor in hypotension and platelet activation induced by infusion of thrombolytic agents in rabbits.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1572886

Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1572886

Heparin-associated thrombocytopenia and thrombosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1572886

Streptokinase induces intravascular release of platelet-activating factor in patients with acute myocardial infarction and stimulates its synthesis by cultured human endothelial cells.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1572886

Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1572886

DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1572886

A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1572886

Inhibition of platelet aggregation with a glycoprotein IIb-IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction

27 November 2018

1 reference

12 December 2020

A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study

1 reference

12 December 2020

Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis

1 reference

12 December 2020

Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator

1 reference

12 December 2020

Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4

1 reference

12 December 2020

DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa.

1 reference

12 December 2020

Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial

1 reference

12 December 2020

Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase

1 reference

12 December 2020

Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa

1 reference

12 December 2020

Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators

1 reference

12 December 2020

Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJP.0704182

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11487531%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11487531%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

PubMed publication ID

11487531

1 reference